ICER Analytics™ launched to accelerate the real-world application of ICER reports -- helping payers, the life science industry, and health care policy makers move from insight to action.

ICER #WeeklyView: ICER’s acute pain Evidence Report, our retinitis pigmentosa Draft Report, & more on PBM reform

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Advanced Retinitis Pigmentosa:

Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Acute Pain:

ICER #WeeklyView: ICER snapshots, suzetrigine's approval, & Trump admin on IRA negotiations

On Feb 5th, ICER's Dan Ollendorf will be speaking at the International Conference on Drug Pricing and Affordability. During a panel, Dr. Ollendorf will discuss how #HTA can shape drug pricing and coverage decisions. Register here for the webinar: #heor

ICER's President and CEO @sarahkemond will be attending the @OliverWyman Life Sciences Symposium in Philadelphia on February 10-11. She'll lead a discussion on “Valuing Biopharma Innovation: Navigating The Drug Pricing Debate.” Learn more here: #OWHIC

ICER #WeeklyView: ICER’s Launch Price and Access Report, President Trump's health care EOs, & the future of CMS drug negotiations

Institute for Clinical and Economic Review Announces New Annual Launch Price and Access Report for 2025:

ICER #WeeklyView: ICER’s public comment periods, more on the IRA drug price negotiations, & the FTC’s latest PBM report

ICER #WeeklyView: CMS’s MFP explanations, a new topic announcement, & January price hikes

New Year, New Platform! ICER has expanded our social media presence to Bluesky. Follow us here: #Bluesky #HTA #HEOR

Institute for Clinical and Economic Review to Assess Treatments for Spinal Muscular Atrophy:

ICER #WeeklyView: The most important ICER stories of 2024

Institute for Clinical and Economic Review Publishes Fourth Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease:

ICER #WeeklyView: ICER’s Unsupported Price Increase Report, acute pain Draft Evidence Report, & FDA’s latest on accelerated approval

RT @RxPricing: 🚨 #BigPharma's unjustified price hikes on just five Rx drugs cost U.S. patients & the health care system $815 MILLION in 202…

@alsadvocacy Apologies for the error with the original link. Here is the link:

RT @GlobalDiaBEATes: List price increases are far above the rate of inflation 4 many of the costliest drugs resulting in over $800M in exce…